Glucose monitor after delivery to gauge type 2 diabetes risk in gestational diabetes
Tests a wearable glucose monitor after childbirth in women who had gestational diabetes.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 28 Sept 2025
- Expected to end
- Jun 2030
- Type of study
- Interventional
- Treatments tested
- Continuous Glucose Monistor
- Record updated
- 4 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with gestational diabetes who plan to deliver at certain UCLA hospitals. A glucose sensor is worn for 24 hours after birth.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Gestational diabetes confirmed by the 2-step approach
- Earlier treatment
- Cannot be using metformin or steroids. No terbutaline within 4 hours of delivery.
Main reasons for not taking part
- Diabetes before pregnancy (type 1 or type 2)
- Pregnancy with more than one baby
- Heavy bleeding after delivery
- Allergy to medical-grade adhesive or skin lesions where the sensor goes
- Cystic fibrosis or MODY
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Prenatal care at UCLA Health
- Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
- Confirmed gestational diabetes diagnosis based on 2-step approach
- Maternal age >= 18 years
Who cannot take part
- Steroid use
- Pre-gestational diabetes (T1DM or T2DM)
- Intra-amniotic infection by clinical criteria
- Postpartum hemorrhage
- Known allergy to medical-grade adhesive
- MODY (mature onset of diabetes in the young)
- Multifetal gestation
- Maternal ICU admission
- Presence of skin lesions at anticipated CGM application site
- Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
- Metformin use
- Terbutaline use within 4 hours of delivery
- Cystic fibrosis
Where in United States
- University of California, Los AngelesLos Angeles, United StatesContact: Dana Levin-Lopez, MPHTaking people
About the trial
What the trial wants to find out
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.
Read full original descriptionShow less
Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.
The group in the trial
- Continuous Glucose MonitorOther group
Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data.
Treatment: Continuous Glucose Monistor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial
- Plain-language title
- Glucose monitor after delivery to gauge type 2 diabetes risk in gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 March 2026